AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 291 min read$INSM

Insmed Reports Q3 Revenue of $524.4 Million and Raises 2026 Guidance

Insmed reported Q3 2026 revenue of $524.4M, up 268% YoY, and a net loss of $100.3M. The company raised 2026 revenue guidance for BRINSUPRI and ARIKAYCE. BRINSUPRI generated $400.1M, ARIKAYCE $124.4M. Insmed launched BRINSUPRI in Japan and received FDA acceptance for ARIKAYCE's supplemental application.

Original reporting
tradingview.com
Published Oct 29, 2026, 11:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Insmed Reports Q3 Revenue of $524.4 Million and Raises 2026 Guidance — source image
Source · tradingview.com
Decision brief

The 30-second read

$INSMBullishHigh
01

Why it matters

The Q3 earnings beat and guidance increase provide a clear catalyst for short-term price appreciation, while upcoming regulatory milestones add longer-term upside potential.

02

Market read

The earnings release and guidance lift are material for investors in biotech and could influence sector sentiment.

03

What to watch

Potential headwinds from competition in the NCFB space and pending FDA decisions could affect future performance.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Insmed Inc. (INSM) is a specialty biopharmaceutical company focused on respiratory diseases, with products BRINSUPRI and ARIKAYCE.

Company-level read

Ticker impact

$INSMBullishHigh confidence
Context

Insmed reported Q3 2026 revenue of $524.4 million and raised its full-year 2026 revenue guidance.

Expected impact

upward pressure as the market prices in the higher revenue outlook.

Evidence & confidence

Revenue beat and guidance lift are fresh, material information that can move the share price immediately.

Market effects

Sector

Biotech sector may see modest uplift as a peer demonstrates strong pipeline progress.

Regional

U.S. biotech stocks could benefit from the positive earnings surprise.

Global

Limited to investors focused on specialty pharma and respiratory therapeutics.

Counterpoint

What could challenge this read

Guidance raise may already be priced in; execution risk on upcoming regulatory milestones could temper upside.

Key entities

  • Company
    Insmed Inc.

    Specialty biopharma focused on respiratory therapies.

Read at source← All news

StoryInsmed raises 2026 revenue guidance after strong third-quarter results

Also covered by

4 outlets

Related articles

OCT 30
$INSMHighAI 8/10

Why Did Insmed Stock Jump?

Insmed (INSM) shares rose 15.1% on October 29, 2026, after reporting Q3 2026 results. Revenue of $524.4M beat estimates, but loss per share was wider. BRINSUPRI revenue grew 29% QoQ, and guidance was raised. R&D and sales costs increased 40% YoY. The stock is down 32.5% over the past year.

finance.yahoo.com2 min
OCT 30
$INSMHighAI 9/10

Goldman Sachs reiterates Insmed stock rating on Brinsupri beat

Goldman Sachs maintained a Buy rating and $194 price target for Insmed (INSM) after its quarterly results beat estimates. Brinsupri revenue was $400.1M, exceeding expectations. Insmed raised its 2026 guidance for Brinsupri to $1.35B-$1.40B. The stock rose 19.5% to $111.59. Analysts have revised earnings upwards, with price targets ranging from $165 to $243.

investing.com2 min
OCT 29
$INSMMed

Insmed Inc (INSM) Q3 2026 Earnings Call Highlights: Brinsupri Hits Blockbuster Status

Insmed Inc (INSM) reported positive Q3 2026 earnings, with Brinsupri showing strong persistency and revenue trends. The company expects cash flow positivity in 2027 and provided updates on TPIP trials and Erakase's label expansion. Dr. Martina Flammer highlighted growth opportunities in comorbid COPD and asthma bronchiectasis, with data expected in mid-2027. Insmed also discussed AI use for patient identification and the potential impact of real-world studies.

finance.yahoo.com2 min
OCT 29
$INSMMedAI 8/10

What Insmed (INSM) Said on Its Q3 Earnings Call

Insmed (INSM) reported Q3 earnings, highlighting AI diagnostic tools for bronchiectasis, expected to share findings in 2027. FDA granted priority review for ARIKAYCE's sNDA, with a target action date of Jan. 28, 2027. The company expects cash-flow positivity in 2027. Insmed also provided updates on its pipeline, including TPIP and INS1033 programs. Cost of product revenues was $78.2 million, or 14.9% of revenue, with combined R&D and SG&A expenses up 40% year over year.

finance.yahoo.com2 min
OCT 29
$INSMHighAI 8/10

Insmed (INSM) Q3 2026 Earnings Call Transcript

Insmed (INSM) reported Q3 2026 revenue of $400.1M for BRINSUPRI, up 29% sequentially. The company raised its 2026 revenue guidance to $1.35B-$1.4B. Insmed expects its lead respiratory assets to exceed $14B in peak sales, with BRINSUPRI potentially reaching $7B+ and TPIP $6B+.

finance.yahoo.com3 min